STAT

Avidity, FDA reach agreement on accelerated filing of rare disease drug

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
Nasdaq

12 Analysts Assess Avidity Biosciences: What You Need To Know

12 analysts have shared their evaluations of Avidity Biosciences (NASDAQ:RNA) during the recent three months, expressing a mix of bullish and bearish perspectives. The following table encapsulates ...
The American Journal of Managed Care

Avidity Biosciences Gains FDA Orphan Drug Designation for Patients With DMD

Sarah Boyce, president and CEO at Avidity Biosciences, discusses her leading role at the company, as well as antibody oligonucleotide conjugate drug, AOC 1044, currently in development for Duchenne ...
Nasdaq

Avidity Biosciences Announces Oversubscribed $400 Million Private Placement

Funding from new and existing investors, including Adage Capital Partners LP, Boxer Capital, Casdin Capital, LLC, Farallon, Janus Henderson Investors, RA Capital Management, RTW Investments, ...
Seeking Alpha

Avidity Biosciences Receives Orphan Drug Designation in Japan for Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1

SAN DIEGO, April 8, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates ...
Seeking Alpha

Novartis' Deal For Avidity And Its Late-Stage Muscle Disease Assets Has Caveats

Novartis AG will acquire Avidity Biosciences, Inc. for $12bn, aiming to strengthen its neuroscience franchise and xRNA strategy with late-stage muscle disease assets. The deal brings three late-stage ...